CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
about
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cellsNew Findings on Breast Cancer Stem Cells: A ReviewSpotlight on ixazomib: potential in the treatment of multiple myelomaCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Targeting the Pim kinases in multiple myelomaThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesChemokine receptor-specific antibodies in cancer immunotherapy: achievements and challengesA meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancerStem cell competition: finding balance in the nicheTargeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modelingIn vivo acoustic and photoacoustic focusing of circulating cells.The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Cell labeling approaches for fluorescence-based in vivo flow cytometryThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapyBone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosisReplication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycPerformance of computer vision in vivo flow cytometry with low fluorescence contrast.In vivo flow cytometry: a horizon of opportunities.Tomographic sensing and localization of fluorescently labeled circulating cells in mice in vivoPositron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinomaRole of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.Expression and function of CXCL12/CXCR4 in rat urinary bladder with cyclophosphamide-induced cystitisUsing combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Stromal reengineering to treat pancreas cancerAssociation between mobilization regimen and PFS after auto-SCT for multiple myeloma.Stem cells and bone diseases: new tools, new perspectiveEngineered nanomedicine for myeloma and bone microenvironment targeting.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targetingInhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibTracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLBone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.The sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaCXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.Instrument for fluorescence sensing of circulating cells with diffuse light in mice in vivo.Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.
P2860
Q26744596-FBC5E9CC-D138-46AE-A2B6-C84E59AB0C87Q26771894-719492F6-0D2D-4B72-A3A8-C68DE230729AQ26774440-5D9673DA-236B-49F3-BB46-1C70E9326B80Q26785497-CB63F49E-0CBD-4462-9443-9C0105508153Q26799499-56130089-AE78-40A8-8482-01BCE09D4907Q26822700-1AAA27DE-BC55-40AD-855C-61BEC184D171Q26866236-B2202ADD-E00C-4172-A6CD-75978D005F22Q26998677-2AE3E734-BFF2-45AE-BC57-DEEBB78C5F48Q27009202-879C8149-8D24-46AF-8ACC-AF0765B595DFQ27334339-B3DB5D88-3E6F-482A-BA1D-2B941581C138Q27346697-414396B7-39D1-419A-BE4F-45D538E13C89Q27687567-6CE84379-4D53-401F-A820-0538E68C0027Q27693903-D9D584B2-A2FC-4213-9FCC-F549A2DA9D87Q28067724-67AF387F-65D3-45E1-9003-BE35C643EBCEQ28483881-C8A32EF1-34CB-4527-AF79-4C99EDB2F269Q28559676-ADB6D495-6843-40E7-BA22-0573903FD319Q30387440-6F1A1953-3DC5-4ECB-9424-1675002E57EBQ30454382-E8D9C384-2959-4807-BB6E-88BDF79896D5Q30533188-9D552A6B-E4A9-4B27-85FB-6978FE063E59Q30836426-F80315F3-2B34-4702-94E7-5C11BA673388Q33555276-BA2E5653-9A1C-409C-80C8-55C716B6104AQ33559560-60C1BA2F-53E6-4474-AD8F-1D702F08047DQ33695185-64458F32-1624-4568-B4E7-DC4520FE6D40Q33727844-D6915F2B-E68C-4E7A-BFBA-8D710847ADAEQ33745075-F07D6415-76E4-4839-83C1-E97B4CEABE7EQ33798887-36FE18E3-CAD0-48AF-A043-7D47FF352E25Q33827708-F51C3439-8012-4B22-A9A2-C2FE4AE9F577Q33889676-276EDEA4-6BF5-424B-8FAB-36E7ECA900AFQ33925049-744F3209-F681-4F82-ABF5-FB117820FA9DQ33926003-1CF550ED-70CD-4486-BC09-359AE78BEF09Q33956990-7AB14B82-8DE6-45D1-B5AF-69C975C8B41FQ34010429-D0EEB9E2-7D2E-4E53-8D61-F2DF4A5A3722Q34013386-1D9E5981-E210-4E38-8595-942B8D8EF8CBQ34020937-FE05241C-923C-4066-B9D3-97AB241F147BQ34042250-4FDFCE5A-C247-4849-B037-9586CBF73E80Q34164197-902E099A-4C0B-444A-9B11-D2AA7BF48D06Q34170367-F3BAEBD8-3A90-4447-9612-6C0A74F29B6CQ34209313-D3C47873-8DC3-43A1-AEF5-1A234B2163F3Q34232060-F0D46D4C-5D32-4E95-8EAD-1E6BEF9316DAQ34256144-6F310AFF-78C8-4BB6-A6CE-936AE114EE40
P2860
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@ast
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@en
type
label
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@ast
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@en
prefLabel
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@ast
CXCR4 inhibitor AMD3100 disrup ...... their sensitivity to therapy.
@en
P2093
P2860
P50
P1433
P1476
CXCR4 inhibitor AMD3100 disrup ...... s their sensitivity to therapy
@en
P2093
Abdel Kareem Azab
Alicia L Carlson
Anne-Sophie Moreau
Barrett J Rollins
Beatriz Ospina
Charles P Lin
Clemens Alt
Costas Pitsillides
P2860
P304
P356
10.1182/BLOOD-2008-10-186668
P407
P577
2009-01-12T00:00:00Z